<DOC>
	<DOCNO>NCT03023553</DOCNO>
	<brief_summary>This study examine immune response seasonal influenza vaccine single cell nasal passage compare cell circulate blood .</brief_summary>
	<brief_title>The Human Mucosal Immune Responses Influenza Virus ( SLVP026 )</brief_title>
	<detailed_description>Using state-of-the-art technology , investigator hope information learn study help identify describe important factor early-stage development influenza immunity possibly lead development effective vaccine . This study conduct healthy male female volunteer 18-30 year age receive one two seasonal influenza vaccine type , intramuscular standard trivalent inactivate influenza vaccine ( TIV ) live , attenuated influenza vaccine ( LAIV ) give intranasal spray . Participants divide two group . The control group receive 2012-2013 formulation standard intramuscular trivalent inactivate influenza vaccine ( TIV ) . A blood sample nasopharyngeal swab sample ( one nostril ) collect single visit , Day 0 . For live , attenuated influenza vaccine ( LAIV ) group , first visit , receive single administration 2012-2013 formulation LAIV . At second study visit two day later , provide blood sample two nasopharyngeal swab sample ( one nostril ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Otherwise healthy , ambulatory adult age 1830 year 2 . Willing complete informed consent process . 3 . Availability followup Day 2 ( LAIV Group ) 4 . Acceptable medical history review inclusion/exclusion criterion vital sign . 1 . Prior offstudy vaccination current 20122013 seasonal TIV LAIV 2 . Allergy egg egg product , vaccine component , include thimerosal ( TIV multidose vial ) , gentamicin , gelatin , arginine MSG ( LAIV ) . 3 . Lifethreatening reaction previous influenza vaccination 4 . Asthma history wheezing ( except control study assign receive TIV ) . 5 . Active systemic serious concurrent illness , include febrile illness day vaccination 6 . History immunodeficiency ( include HIV infection ) 7 . Known suspected impairment immunologic function , include , limited , clinically significant liver disease , diabetes mellitus treat insulin , moderate severe renal disease , chronic disorder , opinion investigator , might jeopardize volunteer safety compliance protocol . 8 . Blood pressure &gt; 150 systolic &gt; 95 diastolic first study visit 9 . Hospitalization past year congestive heart failure emphysema . 10 . Chronic Hepatitis B C. 11 . Recent current use immunosuppressive medication , include systemic glucocorticoid . Corticosteroid nasal spray allergies topical steroid permissible . Inhaled steroid condition asthma permissible volunteer LAIV group . 12 . Participants close contact anyone severely weaken immune system receive LAIV ( LAIV Group ) . 13 . Malignancy , squamous cell basal cell skin cancer ( include solid tumor breast cancer prostate cancer recurrence past year , hematologic cancer leukemia ) . 14 . Autoimmune disease ( include rheumatoid arthritis treat immunosuppressive medication Plaquenil , methotrexate , prednisone , Enbrel ) , opinion investigator , might jeopardize volunteer safety compliance protocol . 15 . History blood dyscrasia , renal disease , hemoglobinopathies require regular medical follow hospitalization precede year 16 . Use anticoagulation medication Coumadin Lovenox , antiplatelet agent aspirin ( except 325 mg. aspirin per day ) , Plavix , Aggrenox must review investigator determine would affect volunteer 's safety.. 17 . Receipt blood blood product within past 6 month plan use study . 18 . Medical psychiatric condition occupational responsibility preclude participant compliance protocol 19 . Inactivated vaccine 14 day prior vaccination plan nonstudy vaccination prior completion last study visit . 20 . Live , attenuate vaccine within 60 day vaccination plan nonstudy vaccination prior completion last study visit . 21 . History GuillainBarr√© Syndrome 22 . Pregnant lactate woman 23 . Use investigational agent within 30 day prior enrollment plan use investigational agent prior completion study visit . 24 . Donation equivalent unit blood within 6 week prior enrollment plan donation prior completion last visit . 25 . Any condition , opinion investigator , might interfere volunteer safety , study objective ability participant understand comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Trivalent , inactivate influenza vaccine</keyword>
	<keyword>Live , attenuate influenza vaccine</keyword>
	<keyword>Nasopharyngeal swab</keyword>
	<keyword>Young adult</keyword>
</DOC>